Malaria - Pipeline Analysis - Drug Development Strategies by Therapies Employed, RoA, Targets, Mechanism of Action, and Therapeutic Modalities

This pipeline analysis report provides detailed insights into the clinical trial landscape of malaria therapeutics, including molecules at the pre-clinical and discovery stage. This malaria diagnostics market report also covers information about the therapeutic assessment of the pipeline molecules based on therapies employed, route of administration, target, mechanism of action (MoA), and therapeutic modalities. Also, the report provides an analysis of the companies currently involved in the development of pipeline molecules for malaria including Astellas Pharma Inc., Bharat Biotech Ltd., Carna Biosciences Inc., Eisai Co. Ltd., Lipotek Pty Ltd., Merck KGaA, Novartis AG, Nurex Srl, Sanaria Inc., Sanofi, Takeda Pharmaceutical Co. Ltd., and VLP Therapeutics.

Overview of the Therapeutic Pipeline for Malaria

It has been observed that children under five years of age are the most vulnerable group affected by malaria. Children with severe malaria very often develop one or more symptoms, including severe anemia, respiratory distress in relation to metabolic acidosis, or cerebral malaria. On the other hand, multi-organ failure is very common in adults with malaria. Although in malaria-endemic areas, people may develop partial immunity, allowing asymptomatic infections to occur, the demand for effective combination and intravenous therapeutics is increasing. The drugs are formulated to eliminate Plasmodium parasites, which causes the disease. Among the several Plasmodium species, P. falciparum is the most lethal if left untreated. Globally, the incidence and prevalence of malaria are decreasing every year. However, The WHO African Region continues to carry a disproportionately high share of the global malaria burden. In 2018, the region was home to 93% of malaria cases and 94% of malaria deaths.

Most of the molecules in the pipeline are being developed for monotherapy and oral route of administration. Over 35% of the molecules in the pipeline are currently in the discovery and pre-clinical stages. In addition to the active molecules, there are also a number of pipeline products that have been either discontinued from development or are currently dormant.

Companies Covered 

This malaria diagnostics market report provides a detailed analysis of companies that are involved in the development of molecules for the treatment of malaria. The report provides information on the number of molecules currently developed by companies and the various stages of these molecules. The report also covers details on the collaboration of these companies with institutions to utilize the available technologies for further development and commercialization of molecules.

Some of the companies covered in this pipeline analysis report include -

• Astellas Pharma, Inc.
• Bharat Biotech Ltd.
• Carna Biosciences, Inc.
• Eisai Co. Ltd.
• Lipotek Pty Ltd.
• Merck KGaA
• Novartis AG
• Nurex Srl
• Sanaria Inc
• Sanofi
• Takeda Pharmaceutical Co. Ltd.
• VLP Therapeutics

Malaria - Pipeline Analysis: Therapeutic Assessment of the Molecules by RoA

• Oral
• Intramuscular
• Intravenous
• Unknown

The intramuscular route of administration (RoA) has more rapid onset action compared with oral administration. It is also more effective than intravenous molecules as a few drugs irritate the veins, and there are instances wherein the vein cannot be located. However, most of the molecules that are currently in the pipeline are being developed for oral administration.

Malaria - Pipeline Analysis: Therapeutic Assessment of the Molecules by Therapy

• Monotherapy
• Combination therapy

Monotherapy uses a single drug to treat a disorder. Most of the molecules that are currently in the pipeline to treat malaria are being developed as monotherapy drugs.

Malaria - Pipeline Analysis: Key Highlights of the Report  

• What are the therapy molecules used in the various development stages of the parasite causing malaria?
• What are the companies that are currently involved in the development of therapeutic molecules for malaria?
• Insight into discontinued/dormant molecules with appropriate reasoning
• What are the major regulatory authorities approving drugs in various regions?
• Detailed profiling of each active molecule

We can help! Our analysts can customize this report to meet your requirements.Get in touch